ArticleTurk pediatri arsivi2018
Turkish Neonatal Society guideline on prevention and management of bronchopulmonary dysplasia.
Article in Turk pediatri arsivi, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Assessment of survival and neonatal morbidity rates of very low birth weight infants in Türkiye: Turkish Neonatal Society SECRETS (TNS-SECRETS) study.Scientific reports · 2026Observational
- Short-Term Effects of Spironolactone/Hydrochlorothiazide on Respiratory Support in Preterm Infants with Bronchopulmonary Dysplasia: A Retrospective Before-After Study.Journal of clinical medicine · 2026Article
- Caffeine use in preterm neonates: national insights into Turkish NICU practices.Frontiers in pediatrics · 2025Article
- Enhanced vs. standard low dose dexamethasone treatment on respiratory outcomes of preterm infants with bronchopulmonary dysplasia.Frontiers in pediatrics · 2025Article
- Comparison of Bilevel Volume Guarantee and Pressure-Regulated Volume Control Modes in Preterm Infants.Children (Basel, Switzerland) · 2023Article
- Pathophysiologically Based Ventilatory Management of Severe Bronchopulmonary Dysplasia.Turkish archives of pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scientific and technological advances in perinatology and neonatology have led to an increased rate of survival and decreased incidences of various neonatal morbidities. However, the incidence of bronchopulmonary dysplasia has remained almost the same for years in very-low-birth-weight preterm infants. Although bronchopulmonary dysplasia is the leading cause of chronic respiratory morbidity in small preterms, no substantial improvement has been achieved in prevention and treatment strategies to date. Currently, postnatal very-low-dose corticosteroids, caffeine, and vitamin A seem to be the drugs of choice, and stem cell therapy appears to be the most promising treatment modality for the future. In this guideline, which was prepared by the Turkish Neonatal Society, recent evidence-based recommendations for the prevention and treatment of bronchopulmonary dysplasia are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.